ClinicalTrials.gg
CompletedNCT05923281Updated Dec 11, 2025

A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

A Phase 3 interventional study of K-877 0.2 mg/day (once daily) and K-877 0.4 mg/day (once daily) in Hypercholesterolemia, sponsored by Kowa Company, Ltd.. Completed at 22 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Kowa Company, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Hypercholesterolemia by Kowa Company, Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Hypercholesterolemia · Kowa Company, Ltd..

Enrollment
11th of 11
71 · median 355
Started
2023
the only one that year
Phase 3
10 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Hypercholesterolemia by Kowa Company, Ltd., this one is the 11th largest by enrollment, is the only one that started in 2023, is one of 10 in phase 3, and was the 10th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 11 studies in Hypercholesterolemia by Kowa Company, Ltd. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Hypercholesterolemia by Kowa Company, Ltd., or all of them as a file.
02

Study summary

To investigate the efficacy and safety of K-877 Extended Release 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with Statin Intolerant* Hypercholesterolemia,using placebo as a controll.

*Statin Intolerant: Adverse events associated with statin use that cause unacceptable disturbances in the user's daily life, resulting in drug discontinuation or dose reduction.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: The person who meet all the following criteria the object to the clinical trial

  1. Patients had to be age 18 years or older at written
  2. Patients with statin intolerant hypercholesterolemia
  3. Patients who have laboratory records with fasting serum TG \<= 150 mg/dL (\<=175 mg/dL when not fasting) within 6 months prior to consent.
  4. Patients with the fasting serum TG \<= 150 mg/dL at screening
  5. Patients who have received dietary or exercise guidance from 12 weeks or more prior to Screening
  6. Patients who apply any of the following risk category with LDL-C level (Friedewald formula) based on JAS2022 at screening

    • Low risk for primary prevention: LDL-C >=160 mg/dL
    • Intermediate risk for primary prevention: LDL-C >=140 mg/dL
    • High risk for primary prevention: LDL-C>=120 mg/dL
    • Secondary prevention: LDL-C>=120 mg/dL

Exclusion Criteria: The person who meet any of the following criteria will be excluded from the study.

  1. Patients who require administration of prohibited drugs during the clinical trial period after written informed consent
  2. Patients with type 1 diabetes and uncontrolled diabetes [(NGSP) >= 10.0 % at Screening]
  3. Patients with uncontrolled thyroid disease
  4. Patients with undergoing LDL apheresis
  5. Patients with cirrhosis or those with biliary obstruction
  6. Patients with familial hypercholesterolemia (homozygotes)
  7. Patients with uncontrolled hypertension (SBP >= 160 mmHg or DBP >= 100 mmHg) at Screening
  8. Patients with an or ALT three times the upper limit at Screening
  9. Patients with an CK four times the upper limit at Screening
  10. Patients with any of the following criteria within 3 months before obtaining informed consent: myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass surgery, stroke, , symptomatic carotid artery stenosis, symptomatic peripheral arterial disease, abdominal aortic aneurysm, uncontrolled severe arrhythmia and decompensated heart failure
  11. Patients who plan to undergo PCI, CABG, carotid artery or peripheral revascularization
  12. Patients with heart failure class III or higher according to cardiac function classification
  13. Patients with malignant tumor or those who are judged to have a high risk of recurrence
  14. Patients with a history of myopathy or rhabdomyolysis due to K-877 (pemafibrate)
  15. Patients with a history of due to K-877 (pemafibrate)
  16. Patients with a history of serious drug allergies (anaphylactic shock, etc.)
  17. Pregnant women, lactating women, women planning to become pregnant or lactating during the study period, or pregnant women*2 who do not use specific methods*1
  18. Patients who have collected 400 mL or more of whole blood within 16 weeks, or 200 mL or more of whole blood within 4 weeks, or blood samples (plasma and components) within 2 weeks before Screening
  19. Patients with alcoholics or drug addicts
  20. Patients who participated in other clinical trials of a drug with new active ingredients within 16 weeks or a drug with an approved active ingredients within 12 weeks prior to administration and received an drug other than placebo,or those who will participate in other clinical trials at the same time as the clinical trial
  21. Patients who have been determined inappropriate by the investigator, etc

    • 1 Acceptable contraceptive methods: oral, implantable/injectable contraceptive hormones, mechanical products [intrauterine devices (IUDs) ,etc] or barrier methods with spermicides (pessaries, condoms, cervical caps, etc)
    • 2 Woman of refers to a woman who is physiologically capable of becoming pregnant with a male partner who has not undergone contraception. However, it does not apply if the investigator confirms that any of the following criteria is met.

      • Patients with hysterectomy or tubal ligation before informed consent
      • women (those who who have passed more than 1 year since their last menstrual period without other medical reasons).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Treatment A

    K-877 0.2 mg/day

    Drug: K-877 0.2 mg/day (once daily)

  • Experimental
    Treatment B

    K-877 0.4 mg/day

    Drug: K-877 0.4 mg/day (once daily)

  • Placebo comparator
    Control A

    Placebo

    Drug: Placebo (once daily)

Interventions

  • DrugK-877 0.2 mg/day (once daily)

    K-877 0.2mg tablet

    Also known as: Pemafibrate 0.2mg/day (once daily)

  • DrugK-877 0.4 mg/day (once daily)

    K-877 0.2mg tablet

    Also known as: Pemafibrate 0.4mg/day (once daily)

  • DrugPlacebo (once daily)

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in LDL-C (formula F).

    Percent change = (measured value at each time point - baseline value) / baseline value

    Time frame: 4, 8, and 12 weeks after administration

Secondary outcomes

  1. Efficacy: % change from baseline in fasting serum LDL-C (mg/dL)(Direct)

    Time frame: 4, 8, and 12 week after administration

  2. Efficacy: % change from baseline in fasting serum HDL-C (mg/dL)

    Time frame: 4, 8, and 12 week after administration

  3. Efficacy: % change from baseline in fasting serum non HDL-C (mg/dL)

    Time frame: 4, 8, and 12 week after administration

  4. Efficacy: % change from baseline in fasting serum TG (mg/dL)

    Time frame: 4, 8, and 12 week after administration

  5. Efficacy: % change from baseline in fasting serum LDL-C(formula F)/HDL-C

    Time frame: 4, 8, and 12 week after administration

  6. Efficacy: % change from baseline in fasting serum non HDL-C/HDL-C

    Time frame: 4, 8, and 12 week after administration

07

Study locations

22 sites
  • Nakayama Clinic
    Aichi, Japan
  • Kohnodai Hospital, National Center for Global Health and Medicine
    Chiba, Japan
  • Tashiro Endocrinology Clinic
    Fukuoka, Japan
  • Central Japan International Medical Center
    Gifu, Japan
  • NTT Medical Center Sapporo
    Hokkaido, Japan
  • Tsukuba Medical Center Foundation Tsukuba Medical Center Hospital
    Ibaraki, Japan
  • Yokohama Minami Kyosai Hospital
    Kanagawa, Japan
  • Kumamoto University Hospital
    Kumamoto, Japan
  • Medical Corporation LONGWOOD Maeda Clinic
    Osaka, Japan
  • OCROM Clinic
    Osaka, Japan
  • Rinku General Medical Center
    Osaka, Japan
  • Koshigaya Municipal Hospital
    Saitama, Japan
  • Saitama Medical University Hospital
    Saitama, Japan
  • Affiliated CENTRAL CLINIC of Higashiyamato Hospital
    Tokyo, Japan
  • Fukuwa Clinic
    Tokyo, Japan
  • Juntendo University Hospital
    Tokyo, Japan
  • Medical Corporation Chiseikai Tokyo Center Clinic
    Tokyo, Japan
  • Mishuku Hospital
    Tokyo, Japan
  • Seiwa Clinic
    Tokyo, Japan
  • ToCROM Clinic
    Tokyo, Japan
  • Tokyo Heart Summit Tokyo Heart Rhythm Hospital
    Tokyo, Japan
  • Tokyo-Eki Center-building Clinic
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Aug 2024, 15 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2023
First posted
Jun 28, 2023
StartActual
May 1, 2023
Primary completionActual
Aug 7, 2024
CompletionActual
Aug 7, 2024
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05923281
Lead sponsor
Kowa Company, Ltd.
Responsible party
Sponsor
First posted
Jun 28, 2023
Start date
May 1, 2023
Primary completion
Aug 7, 2024
Completion
Aug 7, 2024
Last update
Dec 11, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion